KEYNOTE-789
Phase III KEYNOTE-789: Pemetrexed/Platinum Chemotherapy ± Pembrolizumab in TKI-Resistant, EGFR-Mutated, Metastatic Nonsquamous NSCLC

Released: June 09, 2023

Activity

Progress
1
Course Completed